Skip to main content

Table 4 The b12 susceptibility of AE-Env clones containing G185, N185 or E185, and the derived mutants

From: Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site

 

IC50of b12 (μg/ml)a

 

Mutation(s)b

Env clone

Wild-type

N186Q

N197Q

N186Q/N197Q

G185D

G185D/N186Q

E185D/N186Q

G185D/N197Q

N185D/N197Q

E185D/N197Q

G185D/N186Q/N197Q

N185D/N186Q/N197Q

E185D/N186Q/N197Q

21PL2

>40c

 

>40

     

14.64

    

47CC11

>40

 

>40

 

7.62

  

0.03

     

50PB2

>40

 

>40

     

0.02

    

52PB3

>40

 

>40

      

0.36

   

52PL4

>40

 

>40

      

0.27

   

52PL7

>40

>40

>40

>40

        

7.06

60PB2

>40

 

>40

     

16.19

    

60PL2

>40

 

>40

     

>40

    

62PL1

>40

>40

>40

0.77

8.26

2.32

 

0.04

  

0.01

  

65CC4

>40

1.31

    

0.38

      

98CC2

>40

 

>40

 

>40

  

5.07

     

101PL1

>40

>40

>40

12.98

       

0.14

 

102CC2

>40

 

12.20

      

0.23

   

104PB4

>40

 

>40

     

>40

    
  1. aIC50 of b12 for suppressing viral replication was calculated using GraphPad Prism 5 software. Data are shown as the means of at least three independent experiments.
  2. bSingle or multiple amino acid mutations were introduced into AE-Env-recombinant viruses. Amino acid numbering is based on HXB2 Env gp120.
  3. cIC50 is >40 μg/ml.
Back to article page

Retrovirology

ISSN: 1742-4690

Contact us